Patent Application
20250230184
The disclosure relates to a compound, pharmaceutical composition, kit for capped RNA transcript, and method for in vitro.
The synthesis of messenger RNA (mRNA) through in vitro transcription has become a crucial tool for introducing exogenous genes and expressing genetic information. It is widely used in the treatment and prevention of diseases. Industrial-scale preparation of mRNA using a one-pot in vitro transcription (IVT) reaction has the advantages of simple process and low cost.
Capping analogs can enhance the translation efficiency of messenger RNA (mRNA) andare the critical key raw material in the development of one-pot in vitro transcription processes.
According to embodiments of the disclosure, the disclosure provides a compound such as a cap analog. The compound of the disclosure may have a structure represented by Formula (I), Formula (II), or Formula (III)
wherein A1 and A2 are independently
R1 and R2 may be hydrogen, methyl or phenyl group; Q1 may be single bond or —CH2—;
Y1 and Y3 may be independently —O—,
Y2 and Y4 may be independently —O—,
Q2, Q5, Q6 and Q7 may be independently —CH2—, or
Q3 and Q4 may be independently —O—, —CH2—, or —CCl2—; R3 may be C1-C6 alkyl group, or
R4 may be hydrogen or methyl; R5, R6, and R7 may be independently hydrogen, methyl or phenyl group; Y5 may be
R8 may be C1-C6 alkyl group, C4-C8 cycloalkyl group, phenyl group, benzyl group or C3-C5 heterocyclic group; and R9 and R10 are independently hydrogen, C1-C6 alkyl group, or benzyl group.
According to embodiments of the disclosure, the disclosure also provides a pharmaceutical composition. The pharmaceutical composition can include a compound having the structure represented by Formula (I), Formula (II), or Formula (III); and an RNA molecule.
According to embodiments of the disclosure, the disclosure provides a kit for a capped RNA transcript. The kit for a capped RNA transcript includes a compound and an RNA polymerase. According to embodiments of the disclosure, the compound has a structure represented by Formula (I), Formula (II), or Formula (III).
According to embodiments of the disclosure, the disclosure also provides a method for in vitro transcription. The method for in vitro transcription includes the following steps. A composition is provided, wherein the composition includes an RNA polymerase, nucleoside triphosphate, and the compound of the disclosure; and a DNA template is contacted with the composition to transcribe the DNA template into RNA in vitro.
A detailed description is given in the following embodiments.
The compound, pharmaceutical composition, kit for capped RNA transcript, and method for in vitro for forming the electrode material and method for preparing the same are described in detail in the following description. In the following detailed description, for purposes of explanation, numerous specific details and embodiments are set forth in order to provide a thorough understanding of the present disclosure. The specific elements and configurations described in the following detailed description are set forth in order to clearly describe the present disclosure. It will be apparent, however, that the exemplary embodiments set forth herein are used merely for the purpose of illustration, and the inventive concept may be embodied in various forms without being limited to those exemplary embodiments.
The disclosure provides a compound, a pharmaceutical composition, a kit for capping RNA transcripts and a method of in vitro transcription. According to embodiments of the disclosure, due to the specific structures of the disclosed compounds, they can serve as cap analogs, enabling the capping reaction of messenger RNA (mRNA) to be completed simultaneously during transcription. As a result, the disclosed compounds may be applied to one-pot in vitro transcription (IVT) processes, achieving the purposes of increasing yield, reducing process costs, enhancing product stability, and improving protein expression capability.
According to embodiments of the disclosure, the compound of the disclosure may have a structure represented by Formula (I), Formula (II), or Formula (III)
wherein A1 and A2 are independently
R1 and R2 may be hydrogen, methyl or phenyl group; Q1 may be single bond or —CH2—; Y1 and Y3 may be independently —O—,
Y2 and Y4 may be independently —O—,
Q2, Q5, Q6 and Q7 may be independently —CH2—, or
Q3 and Q4 may be independently —O—, —CH2—, or —CCl2—; R3 may be C1-C6 alkyl group, or
R4 may be hydrogen or methyl; R5, R6 and R7 may be independently hydrogen, methyl or phenyl group; Y5 may be
R8 may be C1-C6 alkyl group, C4-C8 cycloalkyl group, phenyl group, benzyl group or C3-C5 heterocyclic group; and R9 and R10 are independently hydrogen, C1-C6 alkyl group, or benzyl group.
According to embodiments of the disclosure, the term “single bond” may mean a case where no separate atom is present at the relevant site. For example, in the structures of Formula (I) to (III), when Q1 is single bond, there is no separate atom at the site represented by Q2.
According to embodiments of the disclosure, the alkyl group of the disclosure may be linear or branched alkyl group. According to embodiments of the disclosure, C1-C6 alkyl group of the disclosure may be methyl, ethyl, propyl, butyl, pentyl, hexyl, or an isomer thereof. For example, C1-C6 alkyl group may be methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, or tert-butyl.
According to embodiments of the disclosure, C4-C8 cycloalkyl group of the disclosure may be cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl.
According to embodiments of the disclosure, C3-C5 heterocyclic group of the disclosure may be pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl, tetrahydrofuranyl, or piperidinyl.
According to embodiments of the disclosure, the compound of the disclosure having a structure represented by Formula (I). According to embodiments of the disclosure, when Q2 is —CH2—, Y1 may be
In addition, according to some embodiments of the disclosure, when Q2 is
According to embodiments of the disclosure, the compound of the disclosure having a structure represented by Formula (II). According to embodiments of the disclosure, when Q5 is —CH2—, Y2 may be —O—,
In addition, according to some embodiments of the disclosure, when Q5 is
According to embodiments of the disclosure, the compound of the disclosure has a structure represented by Formula (II). According to embodiments of the disclosure, when Y2 is —O—, Z is
According to embodiments of the disclosure, the compound of the disclosure has a structure represented by Formula (II), and Z may be
According to embodiments of the disclosure, when Q7 is —CH2—, Y4 may be —O—,
According to some embodiments of the disclosure, when Q7 is
According to embodiments of the disclosure, the compound of the disclosure having a structure represented by Formula (III). According to embodiments of the disclosure, when Q6 is —CH2—, Y3 may be
In addition, According to some embodiments of the disclosure, when Q6 is
According to embodiments of the disclosure, the compound may be
wherein R1 may be hydrogen, methyl or phenyl group; Q3 and Q4 may be independently —O—, —CH2—, or —CCl2—; R4 may be hydrogen or methyl; and R8 may be C1-C6 alkyl group, C4-C8 cycloalkyl group, phenyl group, benzyl group or C3-C5 heterocyclic group.
According to embodiments of the disclosure, the compound may be
wherein R1 may be hydrogen, methyl or phenyl group; Q3 and Q4 may be independently —O—, —CH2—, or —CCl2—; Q5 is —CH2—, or
R4 may be hydrogen or methyl; and R8 may be C1-C6 alkyl group, C4-C8 cycloalkyl group, phenyl group, benzyl group or C3-C5 heterocyclic group.
According to embodiments of the disclosure, the compound may be
wherein Q3 and Q4 are independently —O—, —CH2—, or —CCl2—; R4 is hydrogen or methyl; R6 and R7 are hydrogen, methyl or phenyl group; and R8 is C1-C6 alkyl group, C4-C8 cycloalkyl group, phenyl group, benzyl group or C3-C5 heterocyclic group.
According to embodiments of the disclosure, the compound may be
wherein R1 is hydrogen, methyl or phenyl group; R2 is hydrogen or methyl; Q3 and Q4 are independently —O—, —CH2—, or —CCl2—; Q5 is —CH2—, or
R4 is hydrogen or methyl; R8 is C1-C6 alkyl group, C4-C8 cycloalkyl group, phenyl group, benzyl group or C3-C5 heterocyclic group; and R9 and R10 are independently hydrogen, C1-C6 alkyl group, or benzyl group.
According to embodiments of the disclosure, the method for preparing the compound having a structure represented by Formula (I) of the disclosure is not limited, and the preparation may be carried out using the following reaction equation:
According to embodiments of the disclosure, the method for preparing the compound having a structure represented by Formula (II) of the disclosure is not limited, and the preparation may be carried out using the following reaction equation:
According to embodiments of the disclosure, the method for preparing the compound having a structure represented by Formula (III) of the disclosure is not limited, and the preparation may be carried out using the following reaction equation:
According to embodiments of the disclosure, the disclosure provides a pharmaceutical composition, which includes a compound and an RNA molecule. According to embodiments of the disclosure, the compound has a structure represented by Formula (I), Formula (II), or Formula (III), and the compound may covalently bond with the RNA molecule (i.e., it may react with the RNA molecule to form a covalent bond). According to embodiments of the disclosure, the RNA molecule is an mRNA molecule.
According to embodiments of the disclosure, the disclosure provides a kit for capping an RNA transcript, including a compound and an RNA polymerase. According to embodiments of the disclosure, the compound has a structure represented by Formula (I), Formula (II), or Formula (III).
According to embodiments of the disclosure, the kit for capping an RNA transcript of the disclosure may further include an RNA molecule, wherein the RNA molecule is an mRNA molecule.
According to embodiments of the disclosure, the disclosure provides a method for in vitro transcription. The method for in vitro transcription includes the following steps. A composition is provided, wherein the composition includes an RNA polymerase, nucleoside triphosphate, and the compound of the disclosure. And, a DNA template is performed to contact with the composition to transcribe the DNA template into RNA in vitro.
Below, exemplary embodiments will be described in detail with reference to the accompanying drawings so as to be easily realized by a person having ordinary knowledge in the art. The inventive concept may be embodied in various forms without being limited to the exemplary embodiments set forth herein. Descriptions of well-known parts are omitted for clarity, and like reference numerals refer to like elements throughout.
Table 1 lists compounds having the structure represented by Formula (I).
Table 2 lists the compounds having the structure represented by Formula (II) of the disclosure.
Table 3 lists the compound having the structure represented by Formula (III) of the disclosure.
To further illustrate the preparation method of the lipid compounds described in the disclosure, the preparation processes for the compounds described in Examples 1-4, 25, 26, and 33-35 are outlined below.
The structure and the measurement result of nuclear magnetic resonance spectrometry of the compounds used in Examples are listed in Table 4.
(TEA+ is triethylammonium)
1H NMR (500 MHz, D2O) δ 8.09 (s, 1H), 5.89 (d, J = 5.0 Hz, 1H), 4.76-4.74 (m, 1H), 4.55 (s, 1H), 4.30 (s, 1H), 4.19-4.15 (m, 2H).
1H NMR (400 MHz, D2O) δ 8.26 (s, 1H), 8.19 (s, 1H), 6.41 (s, 1H), 4.18 (s, 1H), 4.55 (s, 1H), 4.26 (m, 2H), 3.87 (m, 1H), 3.70 (m, 1H), 3.25 (s, 3H). 31P NMR (400 MHz, D2O) δ 0.25.
1H NMR (400 MHz, D2O) δ 7.81 (s, 1H), 5.73 (s, 1H), 4.44 (s, 1H), 4.37 (s, 1H), 3.99 (d, J = 6.1 Hz, 2H), 3.94 (d, J = 8.6 Hz, 1H), 3.83 (d, J = 8.6 Hz, 1H).
1H NMR (500 MHz, D2O) δ 6.03 (s, 1H), 4.92 (s, 1H), 4.26-4.25 (m, 1H), 4.23-4.22 (m, 1H), 4.17 (s, 3H), 4.15-4.01 (m, 2H), 3.43 (s, 3H).
(TEA+ is triethylammonium)
1H NMR (400 MHz, D2O) δ 5.90 (d, J = 4.4 Hz, 1H), 4.38 (s, 1H), 4.26-4.20 (m, 1H), 4.06-4.01 (m, 2H), 3.97 (s, 3H), 3.38 (s, 1H), 3.35 (s, 3H).
1H NMR (400 MHz, DMSO-d6) δ 8.05 (s, 1H), 7.93 (s, 1H), 7.62 (s, 1H), 6.09 (s, 1H), 5.48 (d, J = 4.0 Hz, 1H), 4.73 (d, J = 7.2 Hz, 1H), 4.32 (s, 1H), 4.28-4.11 (m, 5H), 3.99-3.96 (m, 1H), 3.42 (d, J = 10.8 Hz, 1H), 3.21 (t, J = 6.8 Hz, 2H), 2.88 (s, 3H).
1H NMR (400 MHz, D2O) δ 8.06 (s, 1H), 7.96 (s, 1H), 7.62 (s, 1H), 6.01 (s, 1H), 5.50 (d, J = 4.4 Hz, 1H), 4.91 (s, 1H), 4.35 (s, 1H), 4.29-3.97 (m, 7H), 3.62-3.57 (m, 2H), 3.11 (s, 3H).
1H NMR (500 MHz, D2O) δ 5.97 (s, 1H), 4.87 (s, 2H), 4.37-4.29 (m, 2H), 4.08-4.00 (m, 6H), 3.67 (s, 3H), 3.38 (s, 3H).
1H NMR (400 MHz, D2O) δ 8.49 (s, 1H), 8.07 (s, 1H), 7.87 (s, 1H), 6.03 (d, J = 5.6 Hz, 1H), 5.75 (d, J = 5.6 Hz, 1H), 4.88-4.84 (m, 1H), 4.47-4.42 (m, 2H), 4.39-4.38 (m, 1H), 4.26-4.25 (m, 1H), 4.12 (t, J = 3.6 Hz, 2H), 3.96-3.88 (m, 2H), 3.38 (s, 3H), 3.09 (q, J = 7.2 Hz, 14H), 1.21-1.15 (m, 26H). 31P NMR (162 MHz, D2O) δ 3.20 (s, 1H), −0.90 (s, 1H).
1H NMR (500 MHz, D2O) δ 9.03 (s, 1H), 6.10 (s, 1H), 4.99 (s, 1H), 4.42-4.38 (m, 2H), 4.10-4.08 (m, 5H), 3.63 (ABX, J = 10.0 Hz, 9.5 Hz, 2H), 3.41 (s, 3H).
1H NMR (400 MHz, D2O) δ 8.40 (s, 1H), 7.98 (s, 1H), 7.80 (s, 1H), 5.96 (d, J = 5.6 Hz, 1H), 5.66 (d, J = 5.6 Hz, 1H), 4.78-4.58 (m, 2H), 4.43-3.85 (m, 8H), 3.34 (s, 3H), 2.88 (s, 3H), 3.06 (q, J = 7.2 Hz, 18H), 1.14 (t, J = 7.2 Hz, 27H). 31P NMR (162 MHz, D2O) δ 3.50 (s, 1P), −0.89 (s, 1P).
(TEA+ is triethylammonium)
1H NMR (500 MHz, D2O) δ 8.13 (s, 1H), 5.89 (d, J = 5.5 Hz, 1H), 4.74 (t, J = 5.5 Hz, 6.5 Hz, 2H), 4.46-4.44 (m, 1H), 4.29 (s, 1H), 4.00 (s, 2H).
Compound (A) (2.30 mmol) was added to a stirred solution of 5 mL water, and slowly add acetic acid dropwise to adjust the solution's pH to 4.0. Next, dimethyl sulfate (23.0 mmol) was slowly added. Next, the result was stirred at room temperature for 3 hours. As methylation proceeds, the pH of the mixture decreased to approximately 2.0. Next, a sodium hydroxide aqueous solution (with a concentration of 1M) was added to adjust the pH value of the mixture to 4.0. After stirring for 5 hours at room temperature, the result was extracted by water (10 ml) and washed by dichloromethane (30 ml), and then the water phase was collected. Next, the result was purified by an ion-exchange resin (DEAE) with the extraction solvent being a 0.1M triethylammonium bicarbonate (TEAB) aqueous solution, obtaining Compound (B) (white solid).
The synthesis pathway of the above reaction was as follows:
The measurement results of nuclear magnetic resonance spectrometry of Compound (B) are shown below: 1H NMR (400 MHz, D2O) δ 5.98 (d, J=7.2 Hz, 1H), 4.55 (t, J=4.0 Hz, 1H), 4.49 (t, J=5.4 Hz, 1H), 4.27 (m, 1H), 4.21 (m, 1H), 4.02 (s, 3H), 3.11 (q, J=7.2 Hz, 19H), 1.19 (t, J=7.2 Hz, 29H)
Compound (B) (0.44 mmol), triphenylphosphine (PPh3) (2.18 mmol), imidazole (4.36 mmol), and 2-(pyridin-2-yldisulfanyl)pyridine (2.18 mmol) were dissolved in dimethylformamide (DMF) (2 ml). Under a nitrogen atmosphere, the mixture was stirred at room temperature for 6 hours. Next, the result was dropwisely added into acetone (250 ml) at −20° C. to form a white solid. The precipitate was collected by centrifugation, washed five times with 30 mL of acetone, and dried under vacuum at room temperature, obtaining Compound (C) (white solid).
The synthesis pathway of the above reaction was as follows:
The measurement results of nuclear magnetic resonance spectrometry of Compound (C) are shown below: 1H NMR (400 MHz, MeOD) δ 8.02 (s, 1H), 7.44 (d, J=1.6 Hz, 1H), 6.99 (d, J=1.6 Hz, 1H), 6.02 (d, J=2.8 Hz, 1H), 5.51 (s, 1H), 4.56 (m, 1H), 4.46 (m, 1H), 4.30-4.16 (m, 7H).
At room temperature, Compound (C) (0.06 mmol), Compound (D) (0.05 mmol), and ZnCl2 (0.07 mmol) were added into dimethylformamide (DMF) (1 ml). After stirring under nitrogen atmosphere for 48 hours, ethylenediaminetetraacetic acid (EDTA) aqueous solution (5 ml, with a concentration of 1M) was added into the result. Next, the result was purified by an ion-exchange resin (DEAE) with the extraction solvent being a 0.1M triethylammonium bicarbonate (TEAB) aqueous solution, obtaining Compound (1) (white solid).
The synthesis pathway of the above reaction was as follows:
Next, the measurement results of nuclear magnetic resonance spectrometry of Compound (1) are shown below. 1H NMR (400 MHz, D2O) δ 7.87 (s, 1H), 5.86 (s, 1H), 5.73 (s, 1H), 4.55 (s, 1H), 4.45 (d, J=9.0 Hz, 1H), 4.37-4.43 (m, 2H), 4.05 (s, 3H), 4.04 (d, J=8.5 Hz, 1H), 3.21 (J=7.3 Hz, 18H), 1.28 (t, J=7.5 Hz, 30H). Next, Compound (1) was analyzed using liquid chromatography-mass spectrometry (LC-MS), and M/Z results show. [M]+=812 (C23H33N11O16P3+).
At room temperature, Compound (C) (0.06 mmol), Compound (E) (0.05 mmol), and ZnCl2 (0.07 mmol) were added into dimethylformamide (DMF) (1 ml). After stirring under nitrogen atmosphere for 48 hours, ethylenediaminetetraacetic acid (EDTA) aqueous solution (5 ml, with a concentration of 1M) was added into the result. Next, the result was purified by an ion-exchange resin (DEAE) with the extraction solvent being a 0.1M triethylammonium bicarbonate (TEAB) aqueous solution, obtaining Compound (2) (white solid).
The synthesis pathway of the above reaction was as follows:
Next, the measurement results of nuclear magnetic resonance spectrometry of Compound (2) are shown below: 1H NMR (400 MHz, D2O) δ 7.87 (s, 1H), 5.86 (s, 1H), 5.73 (s, 1H), 4.55 (s, 1H), 4.45 (d, J=9.0 Hz, 1H), 4.37-4.43 (m, 2H), 4.05 (s, 3H), 4.04 (d, J=8.5 Hz, 1H), 3.21 (J=7.3 Hz, 18H), 1.28 (t, J=7.5 Hz, 30H). Compound (2) was analyzed using liquid chromatography-mass spectrometry (LC-MS), and M/Z results show: [M]−=815 (C22H30N10O18P3+).
At room temperature, Compound (F) (0.06 mmol), Compound (G) (0.05 mmol), and ZnCl2 (0.07 mmol) were added into dimethylformamide (DMF) (1 ml). After stirring under nitrogen atmosphere for 48 hours, ethylenediaminetetraacetic acid (EDTA) aqueous solution (5 ml, with a concentration of 1M) was added into the result. Next, the result was purified by an ion-exchange resin (DEAE) with the extraction solvent being a 0.1M triethylammonium bicarbonate (TEAB) aqueous solution, obtaining Compound (3) (white solid).
The synthesis pathway of the above reaction was as follows:
Next, the measurement results of nuclear magnetic resonance spectrometry of Compound (3) are shown below: 1H NMR (500 MHz, D2O) δ 7.97 (s, 1H), 5.71-5.65 (m, 1H), 5.64 (s, 1H), 4.79 (s, 2H), 4.59 (s, 1H), 4.41-4.38 (m, 3H), 4.30 (s, 1H), 4.24 (s, 2H), 3.38 (s, 3H), 3.11 (q, J=7.2 Hz, 17H), 1.19 (t, J=7.2 Hz, 27H). Compound (3) was analyzed using liquid chromatography-mass spectrometry (LC-MS), and M/Z results show: [M+H]+=829 (C23H32N10O18P3+).
At room temperature, Compound (M) (0.06 mmol) was dissolved in a mixed solution of water (0.03 mL) and dimethyl sulfoxide (DMSO) (0.28 mL). Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HCl) (0.10 mmol) was added, followed by the addition of imidazole (0.19 mmol). The result was stirred at room temperature for 4 hours, after which an aqueous solution of magnesium chloride (MgCl2, concentration 3.15 M, 0.03 mL) was added, followed by the addition of Compound (O) (0.04 mmol). The mixture was stirred at room temperature for 16 hours, and then the result was mixed with an aqueous solution of ethylenediaminetetraacetic acid (EDTA, 5 mL, concentration 1 M), wherein the amount of EDTA was three times that of magnesium chloride. Next, the mixture was purified using ion-exchange resin (DEAE) with triethylammonium bicarbonate (TEAB) aqueous solution (concentration 0.1 M) as the eluent. After concentration and drying, the product was redissolved in water, and acetone and sodium perchlorate were added, leading to the formation of a precipitate. The precipitate was centrifuged, washed with acetone, dissolved in water, and freeze-dried to yield Compound (4).
The synthesis pathway of the above reaction was as follows:
Next, the measurement results of nuclear magnetic resonance spectrometry of Compound (4) are shown below: 1H NMR (400 MHz, D2O) δ 8.03 (s, 1H), 5.80-5.77 (2H), 4.89 (s, 1H), 4.68 (t, J=6.0 Hz, 5.0 Hz, 1H), 4.48-4.45 (m, 2H), 4.40-4.35 (m, 2H), 4.32-4.26 (m, 2H), 4.09-4.07 (m, 4H), 3.62 (dd, J=9.0 Hz, 21.0 Hz, 2H), 3.43 (s, 3H). Next, Compound (42) was analyzed using liquid chromatography-mass spectrometry (LC-MS), and M/Z results show: [M+H]+=906.58 (C24H35N11O19P3S+).
At room temperature, Compound (H) (0.06 mmol) was dissolved in a mixed solution of water (0.03 mL) and dimethyl sulfoxide (DMSO) (0.28 mL). Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HCl) (0.10 mmol) was added, followed by the addition of imidazole (0.19 mmol). The result was stirred at room temperature for 4 hours, after which an aqueous solution of magnesium chloride (MgCl2, concentration 3.15 M, 0.03 mL) was added, followed by the addition of Compound (I) (0.04 mmol). The mixture was stirred at room temperature for 16 hours, and then the result was mixed with an aqueous solution of ethylenediaminetetraacetic acid (EDTA, 5 mL, concentration 1 M), wherein the amount of EDTA was three times that of magnesium chloride. Next, the mixture was purified using ion-exchange resin (DEAE) with triethylammonium bicarbonate (TEAB) aqueous solution (concentration 0.1 M) as the eluent. After concentration and drying, the product was redissolved in water, and acetone and sodium perchlorate were added, leading to the formation of a precipitate. The precipitate was centrifuged, washed with acetone, dissolved in water, and freeze-dried to yield Compound (25).
The synthesis pathway of the above reaction was as follows:
Next, the measurement results of nuclear magnetic resonance spectrometry of Compound (25) are shown below: 1H NMR (500 MHz, D2O) δ 9.00 (s, 1H), 8.29 (s, 1H), 8.19 (s, 1H), 8.00 (s, 1H), 6.43 (s, 1H), 5.71 (s, 1H), 5.54 (s, 1H), 4.88 (s, 2H), 4.58 (s, 1H), 4.44 (br, 1H), 4.34-4.20 (m, 5H), 4.14-3.99 (m, 5H), 3.85 (s, 5H), 3.30 (s, 3H), 3.20 (s, 3H). Next, Compound (28) was analyzed using liquid chromatography-mass spectrometry (LC-MS), and M/Z results show: [M+H]+=1171.7 (C34H47N16O24P4+).
At room temperature, Compound (H) (0.06 mmol) was dissolved in a mixed solution of water (0.03 mL) and dimethyl sulfoxide (DMSO) (0.28 mL). Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HCl) (0.10 mmol) was added, followed by the addition of imidazole (0.19 mmol). The result was stirred at room temperature for 4 hours, after which an aqueous solution of magnesium chloride (MgCl2, concentration 3.15 M, 0.03 mL) was added, followed by the addition of Compound (J) (0.04 mmol). The mixture was stirred at room temperature for 16 hours, and then the result was mixed with an aqueous solution of ethylenediaminetetraacetic acid (EDTA, 5 mL, concentration 1 M), wherein the amount of EDTA was three times that of magnesium chloride. Next, the mixture was purified using ion-exchange resin (DEAE) with triethylammonium bicarbonate (TEAB) aqueous solution (concentration 0.1 M) as the eluent. After concentration and drying, the product was redissolved in water, and acetone and sodium perchlorate were added, leading to the formation of a precipitate. The precipitate was centrifuged, washed with acetone, dissolved in water, and freeze-dried to yield Compound (26).
The synthesis pathway of the above reaction was as follows:
Next, the measurement results of nuclear magnetic resonance spectrometry of Compound (26) are shown below: 1H NMR (500 MHz, D2O) δ 9.13 (s, 1H), 8.33 (d, J=12.5 Hz, 2H), 8.08 (s, 1H), 6.17 (s, 1H), 5.80 (s, 1H), 5.66 (s, 1H), 4.94 (s, 1H), 4.71-4.68 (m, 3H), 4.53-4.47 (m, 3H), 4.40-4.33 (m, 5H), 4.26 (s, 1H), 4.19-4.17 (m, 3H), 3.99 (s, 3H), 3.59-3.54 (m, 5H), 3.43 (s, 3H). Next, Compound (26) was analyzed using liquid chromatography-mass spectrometry (LC-MS), and M/Z results show: [M+H]+=1235.8 (C34H47N16O25P4S+).
At room temperature, Compound (K) (0.06 mmol) was dissolved in a mixed solution of water (0.03 mL) and dimethyl sulfoxide (DMSO) (0.28 mL). Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HCl) (0.10 mmol) was added, followed by the addition of imidazole (0.19 mmol). The result was stirred at room temperature for 4 hours, after which an aqueous solution of magnesium chloride (MgCl2, concentration 3.15 M, 0.03 mL) was added, followed by the addition of Compound (L) (0.04 mmol). The mixture was stirred at room temperature for 16 hours, then mixed with an aqueous solution of ethylenediaminetetraacetic acid (EDTA, 5 mL, concentration 1 M), wherein the amount of EDTA was three times that of magnesium chloride. Next, the mixture was purified using ion-exchange resin (DEAE) with triethylammonium bicarbonate (TEAB) aqueous solution (concentration 0.1 M) as the eluent. After concentration and drying, the product was redissolved in water, and acetone and sodium perchlorate were added, leading to the formation of a precipitate. The precipitate was centrifuged, washed with acetone, dissolved in water, and freeze-dried to yield Compound (33).
The synthesis pathway of the above reaction was as follows:
Next, the measurement results of nuclear magnetic resonance spectrometry of Compound (33) are shown below: 1H NMR (500 MHz, D2O) δ 8.20 (s, 1H), 7.91 (s, 1H), 7.77 (s, 1H), 5.80 (d, J=4.0 Hz, 1H), 5.65 (d, J=4.0 Hz, 1H), 5.54 (s, 1H), 4.75 (s, 1H), 4.66-4.58 (m, 3H), 4.35-4.31 (m, 3H), 4.26 (s, 3H), 4.22 (br, 3H), 4.16 (br, 1H), 4.09 (s, 3H), 3.84 (d, J=14.0 Hz, 6H), 3.23 (s, 6H). Next, Compound (33) was analyzed using liquid chromatography-mass spectrometry (LC-MS), and M/Z results show: [M+H]+=1172.7 (C34H46N15O24P4+).
At room temperature, Compound (M) (0.06 mmol) was dissolved in a mixed solution of water (0.03 mL) and dimethyl sulfoxide (DMSO) (0.28 mL). Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HCl) (0.10 mmol) was added, followed by the addition of imidazole (0.19 mmol). The result was stirred at room temperature for 4 hours, after which an aqueous solution of magnesium chloride (MgCl2, concentration 3.15 M, 0.03 mL) was added, followed by the addition of Compound (L) (0.04 mmol). The mixture was stirred at room temperature for 16 hours, then mixed with an aqueous solution of ethylenediaminetetraacetic acid (EDTA, 5 mL, concentration 1 M), wherein the amount of EDTA was three times that of magnesium chloride. Next, the mixture was purified using ion-exchange resin (DEAE) with triethylammonium bicarbonate (TEAB) aqueous solution (concentration 0.1 M) as the eluent. After concentration and drying, the product was redissolved in water, and acetone and sodium perchlorate were added, leading to the formation of a precipitate. The precipitate was centrifuged, washed with acetone, dissolved in water, and freeze-dried to yield Compound (34).
The synthesis pathway of the above reaction was as follows:
Next, the measurement results of nuclear magnetic resonance spectrometry of Compound (34) are shown below: 1H NMR (400 MHz, D2O) δ 8.24 (s, 1H), 7.95 (s, 1H), 7.80 (s, 1H), 5.84 (d, J=6.0 Hz, 1H), 5.67 (d, J=5.6 Hz, 1H), 5.61 (s, 1H), 4.81-4.72 (m, 1H), 4.69 (s, 1H), 4.35-4.31 (m, 3H), 4.27-4.23 (m, 2H), 4.17-4.11 (m, 4H), 4.08-4.03 (m, 2H), 3.89-3.85 (m, 4H), 3.42 (d, J=9.6 Hz, 1H), 3.37 (d, J=9.6 Hz, 1H), 3.26 (s, 3H), 3.24 (s, 3H), 3.04 (q, J=7.2 Hz, 12H), 2.99 (s, 3H), 1.12 (t, J=7.2 Hz, 19H). Next, Compound (34) was analyzed using liquid chromatography-mass spectrometry (LC-MS), and M/Z results show: [M+H]+=1249.17 (C35H49N16O25P4S+).
At room temperature, Compound (M) (0.06 mmol) was dissolved in a mixed solution of water (0.03 mL) and dimethyl sulfoxide (DMSO) (0.28 mL). Then, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC-HCl) (0.10 mmol) was added, followed by the addition of imidazole (0.19 mmol). The result was stirred at room temperature for 4 hours, after which an aqueous solution of magnesium chloride (MgCl2, concentration 3.15 M, 0.03 mL) was added, followed by the addition of Compound (N) (0.04 mmol). The mixture was stirred at room temperature for 16 hours, then mixed with an aqueous solution of ethylenediaminetetraacetic acid (EDTA, 5 mL, concentration 1 M), wherein the amount of EDTA was three times that of magnesium chloride. Next, the mixture was purified using ion-exchange resin (DEAE) with triethylammonium bicarbonate (TEAB) aqueous solution (concentration 0.1 M) as the eluent. After concentration and drying, the product was redissolved in water, and acetone and sodium perchlorate were added, leading to the formation of a precipitate. The precipitate was centrifuged, washed with acetone, dissolved in water, and freeze-dried to yield Compound (35).
The synthesis pathway of the above reaction was as follows:
Next, the measurement results of nuclear magnetic resonance spectrometry of Compound (35) are shown below: 1H NMR (400 MHZ, D2O) δ 8.28 (s, 1H), 8.01 (s, 1H), 7.86 (s, 1H), 5.91 (d, J=5.5 Hz, 1H), 5.75 (d, J=5.5 Hz, 1H), 5.63 (s, 1H), 4.86-4.84 (m, 3H), 4.75 (s, 2H), 4.66 (t, J=5.5 Hz, 5.5 Hz, 1H), 4.45 (s, 1H), 4.41 (t, J=3.5 Hz, 5.0 Hz, 1H), 4.37-4.33 (m, 2H), 4.27-4.25 (m, 4H), 4.21-4.13 (m, 2H), 3.93 (s, 4H), 3.50 (dd, J=9.0 Hz, 19.5 Hz, 3H), 3.38 (s, 3H), 3.32 (s, 3H), 3.08 (s, 3H), 3.00 (s, 3H). Next, Compound (35) was analyzed using liquid chromatography-mass spectrometry (LC-MS), and M/Z results show: [M+H]+=1263.8 (C36H51N16O25P4S+).
Evaluation of mRNA Yield:
mRNA was produced using in vitro transcription (IVT) technology with cap analogs of Compound (25), (26) and (33) to (35) of the disclosure, as well as the TriLink CleanCap cap analog (product number #N-7113). First, the DNA template plasmid required for IVT was prepared, followed by an enzymatic reaction using T7 enzyme to synthesize mRNA. The resulting mRNA yield was evaluated, and the results are shown in Table 5.
Nuclease-free water was added into the lyophilized carrier RNA to obtain an RNA stock solution (with a concentration of 2 μg/L). Next, the RNA stock solution with various cap analogs (Compound (3) and Jena-ARCA cap analog, with trade number #NU-855L, commercially available from Jena Bioscience) was heated individually at 80° C. for 2 minutes, and then cooled at 0° C. for 5 minutes. Next, the result was placed on a nitrocellulose membrane and exposed to UV illumination to obtain a crosslinked RNA sample.
Then, 2.5% skim milk solution was added to block the nitrocellulose membrane with crosslinked RNA sampleat room temperature for 30 minutes. Thereafter, the primary antibody (Anti-7-methylguanosine (m7G)-Cap mAb) was diluted with the 2.5% skim milk solution and incubated at room temperature for 1 hour. Next, the sample was washed three times with TBST buffer (10 minutes each time). The result was reacted with chemiluminescent reagent (Femto) for 1-3 minutes. Finally, an image analysis of the result was performed via a chemiluminescent imaging system (Fujifilm LAS 4000). The results of the image analysis demonstrate that Compound (3) of the disclosure possesses capping capability comparable to that of commercially available ARCA.
Nuclease-free water was added into the lyophilized carrier RNA to obtain an RNA stock solution (with a concentration of 2 μg/L). Next, deionized water (0.1 mL) and RNA stock solution (10 μL) were mixed with cap analogs (compound (3) and Jena-ARCA cap analog (product number #NU-855L, commercially available from Jena Bioscience)) individually to obtain the samples.
Next, the sample (10 μL) was injected into a column to perform ion-pair reverse-phase ultra-performance liquid chromatography (IP-RP UPLC) using the solution gradient outlined in Table 6 (45 minutes). The absorbance at the UV260 wavelength was monitored. The column used was an oligonucleotide column (Acquity Premier Oligonucleotide C18, manufactured and sold by Waters Corp). A water-based buffer solution (triethylamine acetate buffer, pH 7.0, concentration 100 mM) was used as Solution A, and an acetonitrile (ACN)-based buffer solution (composed of Solution A and ACN in a 3:1 volume ratio) was used as Solution B.
The analysis results indicate that the capping efficiency of Compound (3) of the disclosure is approximately 60.8%, comparable to the capping efficiency of the commercially available Jena-ARCA (approximately 63%).
mRNA was produced using in vitro transcription (IVT) technology with cap analogs of Compound (25), (33) to (35) of the disclosure herein, as well as the TriLink CleanCap cap analog (product number #N-7113). The DNA template used in this process consisted of 40-nucleotide (nt) fragments, and mRNA was synthesized through an enzymatic reaction using T7 enzyme to produce 40-nt mRNAs.
Nuclease-free water was added to the lyophilized carrier RNA to obtain an RNA stock solution (with concentration of 2 μg/L). Deionized water (0.1 mL) and RNA stock solution (10 μL) were then mixed with the 40-nt mRNAs obtained by aforementioned cap analogs to obtain the samples.
Next, 10 μL of each sample was injected into a column and analyzed using ion-pair reversed-phase ultra-performance liquid chromatography (IP-RP UPLC) (45 minutes) according to the solution gradient listed in Table 7. The absorbance value of UV 260 nm was monitored, and the capping efficiency (%) was evaluated based on the obtained results, as shown in Table 8. The column used for the analysis was an oligonucleotide column (Acquity Premier Oligonucleotide C18, manufactured and sold by Waters Corp). A water-based buffer solution (triethylammonium acetate buffer, pH 7.0, concentration 100 mM) was used as Solution A, while an acetonitrile (ACN)-based buffer solution (a mixture of Solution A and acetonitrile in a 3:1 volume ratio) was used as Solution B.
According to the analysis results, it was determined that the capping efficiency of Compounds (25) and (33) to (35) of the disclosure ranges from approximately 71.3% to 100%, which is comparable to the commercially available TriLink CleanCap BTfLuc capping efficiency.
Nuclease-free water was added to the lyophilized carrier RNA to obtain an RNA stock solution (with concentration of 2 μg/L). Next, deionized water (0.1 mL) and RNA stock solution (10 μL) were mixed with cap analogs (compound (3), compounds (25), (33) to (35), and Jena-ARCA capping analog (number #NU-855L, commercially available from Jena Bioscience)) individually to obtain the samples.
HEK293 cells were seeded at 4×104 cells per well in a 96-well culture plate and cultured for 24 hours for attachment. Next, each well was treated with transfection reagent (catalog #Lipofectamine MessengerMax, commercially available from Thermo Fisher, 0.3 μL per well) and samples (50 ng per well). The cells were incubated in a 37° C. incubator with 5% carbon dioxide for 5 hours. Subsequently, 100 μL of signal-activating fluorescence detection reagent (One-Glo Luciferase) was added to each well and incubated at room temperature for 5 minutes to measure luciferase activity. Then, 100 μL of the reaction mixture was pipetted and the fluorescence values were recorded using a microplate reader (GloMax Microplate Reader). According to the results, it has been shown that luciferase mRNA capped with Compound (3), (25) and (33) to (35) of the disclosure exhibited superior nucleic acid translation and protein expression in HEK293 cells compared to mRNA capped with the commercially available Jena-ARCA.
HEK293 (RIG-I+)-IFNβ-fLuc cells were seeded at 1×104 cells per well in a 96-well culture plate and cultured for 24 hours for attachment. Each well was treated with transfection reagent (catalog #Lipofectamine MessengerMax, commercially available from Thermo Fisher, 0.15 μL per well) and samples (200 ng per well). The cells were incubated in a 37° C. incubator with 5% carbon dioxide for 5 hours. Next, 100 L of signal-activating fluorescence detection reagent (One-Glo Luciferase) was added to each well and incubated at room temperature for 5 minutes to measure luciferase activity. Next, 180 μL of the reaction mixture was pipetted, and the fluorescence values were recorded using a microplate reader (GloMax Microplate Reader). According to the results, it has been indicated that luciferase mRNA capped with Compound (3) of the disclosure induced a lower immune response in HEK293 (RIG-I+)-IFNβ-fLuc cells compared to mRNA capped with the commercially available Jena-ARCA.
It will be clear that various modifications and variations can be made to the disclosed methods and materials. It is intended that the specification and examples be considered as exemplary only, with the true scope of the disclosure being indicated by the following claims and their equivalents.
| Number | Date | Country | Kind |
|---|---|---|---|
| 113146768 | Dec 2024 | TW | national |
This application also claims priority of Taiwan Patent Application No. 113146768, filed on Dec. 3, 2024, the entirety of which is incorporated by reference herein. This application claims priority to U.S. Provisional Application Ser. No. 63/615,882, filed on Dec. 29, 2023, the entirety of which is incorporated by reference herein.
| Number | Date | Country | |
|---|---|---|---|
| 63615882 | Dec 2023 | US |
